Antinociceptive effects of NMDA and non-NMDA receptor antagonists in the tail flick test in mice

Pain

Volumn 70, Issue 1, 1997, Pages 31-40

  Lutfy, Kabirullah ^a,c   Cai, Sui Xiong ^b   Woodward, Richard M ^b   Weber, Eckard ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Department of Pharmacokinetics and Drug Metabolism   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AMPA kainate receptors; intrathecal administration; NMDA receptor glycine sites; nociception; non NMDA receptor; tail flick test

Indexed keywords

1 (4 AMINOPHENYL) 4 METHYL 7,8 METHYLENEDIOXY 5H 2,3 BENZODIAZEPINE; 3 AMINO 1 HYDROXY 2 PYRROLIDINONE; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; 6,7 DIBROMO 5 NITRO 2,3 QUINOXALINEDIONE; 6,7 DIMETHYL 5 NITRO 2,3 QUINOXALINEDIONE; ACEA 0593; ACEA 0762; AMPA RECEPTOR; DIZOCILPINE; GLYCINE; KAINIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; INTRATHECAL DRUG ADMINISTRATION; MOUSE; NOCICEPTION; NONHUMAN; OOCYTE; PAIN; PRIORITY JOURNAL; XENOPUS;

ANIMALS; CHEMISTRY; INJECTIONS, SPINAL; MALE; MICE; NOCICEPTORS; PAIN; PAIN MEASUREMENT; RATS; RECEPTORS, AMINO ACID; RECEPTORS, AMPA; RECEPTORS, N-METHYL-D-ASPARTATE; TAIL;

EID: 0030963546     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3959(96)03290-3     Document Type: Article

References (45)

1. Aanonsen, L.M. and Wilcox, G., Nociceptive action of excitatory amino acids in the mouse: effects of spinally administered opioids, phencyclidine and sigma agonists, J. Pharmacol. Exp. Ther., 243 (1987) 9-19.
2. Cahusac, P.M.B., Evans, R.H., Hill, R.G., Rodriquez, R.E. and Smith, D.A.S., The behavioural effects of an N-methylaspartate receptor antagonist following application to the lumbar spinal cord of conscious rats, Neuropharmacology, 23 (1984) 719-724.
3. Coderre, T.J. and Melzack, R., The contribution of excitatory amino acids to central sensitization and persistent nociception after formalin-induced tissue injury, J. Neurosci., 12 (1992) 3665-3670.
4. Coderre, T.J. and Van Empel, I., The utility of excitatory amino acid (EAA) antagonists as analgesic agents. I. Comparison of the antinociceptive activity of various classes of EAA antagonists in mechanical, thermal and chemical nociceptive tests, Pain, 59 (1992) 345-352.
5. Crisp, T., Perotti, J.M., Smith, D.L., Stafinsky, J.L. and Smith, D.J., The local monoaminergic dependency of spinal ketamine, Eur. J. Pharmacol., 194 (1991) 167-172.
6. D'Amour, F.E. and Smith, D.L., A method for determining loss of pain sensation, J. Pharmacol. Exp. Ther., 72 (1941) 74-79.
7. De Conno, F., Caraceni, A., Martini, C., Spoldi, E., Salvetti, M. and Ventafridda, V., Hyperalgesia and myoclonus with intrathecal infusion of high-dose morphine, Pain, 47 (1991) 337-339.
8. Delander, G.E. and Wahl, J.J., Morphine (intracerebroventricular) activates spinal systems to inhibit behavior induced by putative pain neurotransmitters, J. Pharmacol. Exp. Ther., 251 (1989) 1090-1095.
9. Dickenson, A.H. and Ayder, E., Antagonism at the glycine on the NMDA receptor reduces spinal nociception in the rat, Neurosci. Lett., 121 (1991) 263-266.
10. Dickenson, A.H. and Sullivan, A.F., Differential effects of excitatory amino acid antagonists on dorsal horn nociceptive neurones in the rat, Brain Res., 506 (1990) 31-39.
11. Donevan, S.D. and Rogawski, M.A., GYKI 52466, a 2,3-benzodiazepine, is a highly selective, non-competitive antagonist of AMPA/kainate receptor responses, Neuron, 10 (1993) 51-59.
12. Goettl, V.M. and Larson, A.A., Antinociception induced by 3-((±)-2-carboxypiperazine-4-yl-propyl-1-phosphonic acid (CPP), an N-methyl-D-aspartate (NMDA) competitive antagonist, plus 6,7-dinitroquinoxaline-2,3-dione (DNQX), a non-NMDA antagonist, differs from that induced by MK-801 plus DNQX, Brain Res., 642 (1994) 334-338.
13. Huettner, J.E. and Bean, B.P., Block of N-methyl-D-aspartate-activated current by the anticonvulsant MK-801: selective binding to open channels, Proc. Natl. Acad. Sci. USA, 85 (1988) 1307-1311.
14. Hylden, J.L.K. and Wilcox, G.L., Intrathecal morphine in mice: a new technique, Eur. J. Pharmacol., 67 (1980) 313-316.
15. Keana, J.F.W., Kher, S.M., Cai, S.X., Dinsmore, C.M., Glenn, A.G., Guastella, J., Huang, J.-C., Ilyin, V., Lü, Y., Mouser, P.L., Woodward, R.M. and Weber, E., Synthesis and structure-activity relationships of substituted 1,4-dihydroquinoxaline-2,3-diones: antagonists of W-methyl-D-aspartate (NMDA) receptor glycine sites and non-NMDA glutamate receptors, J. Med. Chem., 38 (1995) 4367-4379.
16. Kristensen, J.D., Karlsten, R., Gordh, T. and Berge, O.-G., The NMDA antagonist 3-(2-carboxypiperazine-4-yl)propyl-1-phosphonic acid (CPP) has antinociceptive effect after intrathecal injection in the rat, Pain, 56 (1994) 59-67.
17. Kulagowski, J.J., Baker, R., Curtis, N.R., Leeson, P.D., Mawer, I.M., Moseley, A.M., Ridgill, M.P., Rowley, M., Stansfield, I., Foster, A.C., Grimwood, S., Hill, R.G., Kemp, J.A., Marshall, G.R., Saywell, K.L. and Tricklebank, M.D., 3′-(Arylmethyl)- and 3′-(aryloxy)-3-phenyl-4-hydroxyquinolin-2(1H)-ones: orally active antagonists of the glycine site on the NMDA receptor, J. Med. Chem., 37 (1994) 1402-1405.
18. Leff, P. and Dougall, I.G., Further concerns over Cheng-Prusoff analysis, Trends Pharmacol. Sci., 14 (1993) 110-112.
19. Lehmann, J., Schneider, J., McPherson, S., Murphy, D.E., Bernard, P., Tsai, C., Bennett, D.A., Pastor, G., Steel, D.J., Boehm, C., Cheney, D.L., Liebman, J.M., William, M. and Wood, P.L., CPP, a selective N-methyl-D-aspartate (NMDA)-type receptor antagonist: characterization in vitro and in vivo, J. Pharmacol. Exp. Ther., 240 (1987) 737-746.
20. Le Peillet, E., Babak, A., Moncada, C. and Meldrum, B.S., The non-NMDA antagonists, NBQX and GYKI 52466, protect against cortical and striatal cell loss following transient global ischaemia in the rat, Brain Res., 571 (1992) 115-120.
21. Litchfield, J.T. and Wilcoxon, F., A simplified method of dose-effects experiments, J. Pharmacol. Exp. Ther., 96 (1949) 99-113.
22. Lutfy, K. and Weber, E., Attenuation of nociceptive responses by ACEA-1021, a competitive NMDA receptor/glycine site antagonist, in the mice, Brain Res., in press.
23. Lutfy, K., Woodward, R.M., Keana, J.F.W. and Weber, E., Inhibition of clonic seizure-like excitatory effects induced by intrathecal morphine using two NMDA receptor antagonists: MK-801 and ACEA-1011, Eur. J. Pharmacol., 252 (1994) 261-266.
24. Lutfy, K., Shen, K.-Z., Woodward, R.M. and Weber, E., Inhibition of morphine tolerance by NMDA receptor antagonists in the formalin test, Brain Res., 731 (1996) 171-181.
25. MacDonald, J.F., Bartlett, M.C., Mody, I., Paphapill, P., Reynolds, J.N., Slater, M.W., Schneiderman, J.H. and Pennefather, P.S., Actions of ketamine, phencyclidine and MK-801 on NMDA receptor currents in cultured mouse hippocampal neurones, J. Physiol. (Lond.), 432 (1991) 483-508.
26. Murray, C.W., Cowan, A. and Larson, A.A., Neurokinin and NMDA antagonists (but not a kainic acid antagonist) are antinociceptive in the mouse formalin model, Pain, 44 (1991) 179-185.
27. Näsström, J., Karlsson, U. and Post, C., Antinociceptive actions of different classes of excitatory amino acids receptor antagonists in mice, Eur. J. Pharmacol., 212 (1992) 21-29.
28. Näsström, J., Karlsson, U. and Berge, O.-G., Systemic or intracerebroventricular injection of NMDA receptor antagonists attenuates the antinociceptive activity of intrathecally administered NMDA receptor antagonists, Brain Res., 623 (1993) 47-55.
29. Pekoe, G.M. and Smith, D.J., The involvement of opiate and monoaminergic neuronal systems in the analgesic effects of ketamine, Pain, 12 (1982) 57-73.
30. Raigorodsky, G. and Urca, G., Spinal antinociceptive effects of excitatory amino acid antagonists: quisqualate modulates the action of N-methyl-D-aspartate, Eur. J. Pharmacol., 182 (1990) 37-47.
31. Ren, K., Williams, G.M., Hylden, J.L.K., Ruda, M.A. and Dubner, R., The intrathecal administration of excitatory amino acid receptor antagonists selectively attenuated carrageenan-induced behavioral hyperalgesia in rats, Eur. J. Pharmacol., 219 (1992) 235-243.
32. Sheardown, M.J., Neilsen, E.O., Hansen, A.J., Jacobsen, P. and Honore, T., 2,3-Dihydro-6-nitro-7-sulfamoyl-benzo(F)quinoxaline: a neuroprotectant for cerebral ischemia, Science (Washington DC), 247 (1990) 571-574.
33. Singh, L., Donald, A.E., Foster, A.C., Hutson, P.H., Iverson, L.L., Iverson, S.D., Kemp, J.A., Lesson, P.D., Marshall, G.R., Oies, R.J., Priestley, T., Thorn, L., Tricklebank, M.D., Vass, C.A. and Williams, B.J., Enantiomers of HA-966 (3-amino-1-hydroxypyrrolid-2-one) exhibit distinct central nervous system effects: (+)-HA-966 is a selective glycine/W-methyl-D-aspartate receptor antagonist, but ( - )-HA-966 is a potent γ-butyrolactone-like sedative, Proc. Natl. Acad. Sci. USA, 87 (1990) 347-351.
34. Smith, S.E., Dürmüller, N. and Meldrum, B.S., The non-N-methyl-D-aspartate receptor antagonists, GYKI 52466 and NBQX are anticonvulsant in two animal models of reflex epilepsy, Eur. J. Pharmacol., 201 (1991) 179-183.
35. Stillman, M.J., Moulin, D.E. and Foley, K.E., Paradoxical pain following high-dose spinal morphine, Pain, 4 (Suppl.) (1987) S389.
36. Tallarida, R.J. and Murray, R.B., Manual of Pharmacologic Calculations with Computer Programs, 2nd Edn. Springer-Verlag, New York, 1987, pp. 159-164.
37. Wilcox, G.L., Excitatory neurotransmitters and pain. In: M.R. Bond, J.E. Charlton and C.J. Woolf (Eds.), Proc. VIth World Congress on Pain, IASP, Seattle, 1991, pp. 97-117.
38. Wilding, T.J. and Huettner, J.E., Differential antagonism of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-preferring and kainatepreferring receptors by 2,3-benzodiazepines, Mol. Pharmacol., 47 (1995) 582-587.
39. Wilding, T.J. and Huettner, J.E., Antagonist pharmacology of kainate- and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-preferring receptors, Mol. Pharmacol., 49 (1996) 540-546.
40. Woodward, R.M., Huettner, J.E., Guastella, J., Keana, J.F.W. and Weber, E., In vitro pharmacology of ACEA-1021 and ACEA-1031: systemically active quinoxalinediones with high affinity and selectivity for N-methyl-D-aspartate receptor glycine sites, Mol. Pharmacol., 47 (1995) 568-581.
41. Yaksh, T.L., Spinal opiate analgesia: characteristics and principles of action, Pain, 11 (1981) 293-346.
42. Yaksh, T.L. and Harty, G.J., Pharmacology of the allodynia in rats evoked by high dose intrathecal morphine, J. Pharmacol. Exp. Ther., 244 (1988) 501-507.
43. Yaksh, T.L., Harty, G.J. and Onofrio, B.M., High doses of spinal morphine produce a non-opiate receptor-mediated hyperesthesia: clinical and theoretic implications, Anesthesiology, 64 (1986) 590-597.
44. Yamamoto, T. and Yaksh, T.L., Comparison of the antinociceptive effects of pre- and post-treatment with intrathecal morphine and MK-801, an NMDA antagonist, on the formalin test in the rat, Anesthesiology, 77 (1992) 757-765.
45. Yoburn, B.C., Lutfy, K., Sierra, V. and Tortella, F.C., Tolerance develops to spinal morphine analgesia but not morphine-induced convulsions, Eur. J. Pharmacol., 176 (1990) 63-67.